866-997-4948(US-Canada Toll Free)

Metastatic Hormone Refractory Prostate Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Cancer

No. of Pages : 104 Pages


Global Markets Directs, \'Metastatic Hormone Refractory Prostate Cancer Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. 

It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory Prostate Cancer. Metastatic Hormone Refractory Prostate Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Hormone Refractory Prostate Cancer.
  • A review of the Metastatic Hormone Refractory Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Hormone Refractory Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory Prostate Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Hormone Refractory Prostate Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Metastatic Hormone Refractory Prostate Cancer 10
Metastatic Hormone Refractory Prostate Cancer Therapeutics under Development by Companies 12
Metastatic Hormone Refractory Prostate Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Metastatic Hormone Refractory Prostate Cancer Therapeutics Products under Development by Companies 19
Metastatic Hormone Refractory Prostate Cancer Therapeutics Products under Investigation by Universities/Institutes 20
Companies Involved in Metastatic Hormone Refractory Prostate Cancer Therapeutics Development 21
Bristol-Myers Squibb Company 21
AstraZeneca PLC 22
Genentech, Inc. 23
Bavarian Nordic A/S 24
Millennium Pharmaceuticals, Inc. 25
Astellas Pharma Inc. 26
Teva Pharmaceutical Industries Limited 27
Active Biotech AB 28
Medivation, Inc. 29
Cadila Pharmaceuticals Ltd. 30
Ascenta Therapeutics, Inc. 31
Bellicum Pharmaceuticals, Inc. 32
Metastatic Hormone Refractory Prostate Cancer Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 40
orteronel - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
custirsen sodium - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
tasquinimod - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
enzalutamide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Prostvac - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AZD2171 + Docetaxel + Prednisone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BPX-101 + AP1903 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Zibotentan + Taxotere - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Carboplatin + Etoposide - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Dasatinib + Docetaxel - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Mycobacterium w + Docetaxel - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Ixabepilone + Mitoxantrone Hydrochloride + Prednisone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Ixabepilone + Mitoxantrone Hydrochloride + Prednisone - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
177Lu Radiolabeled Monoclonal Antibody HuJ591 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ZD-4054 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ZD-4054 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CreaVax-PC - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Docetaxel + Prednisone + 177Lu-J591 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Mitoxantrone + Prednisone + Clodronate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
BAY43-9006 + Taxotere - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Mitoxantrone + Prednisone - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
TAK-700 + Prednisone - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AT-101 + Prednisone + Docetaxel - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
BPX-101 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Prostvac + GM-CSF - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ASP-9521 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
RG-7450 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Metastatic Hormone Refractory Prostate Cancer Therapeutics Drug Profile Updates 82
Metastatic Hormone Refractory Prostate Cancer Therapeutics Discontinued Products 96
Metastatic Hormone Refractory Prostate Cancer Therapeutics - Dormant Products 97
Metastatic Hormone Refractory Prostate Cancer Product Development Milestones 99
Featured News & Press Releases 99
Oct 03, 2012: Ipsen And Active Biotech Announce Initiation Of Phase II Trial In Metastatic Castrate-resistant Prostate Cancer With Tasquinimod 99
May 21, 2012: Dendreon To Present PROVENGE Data At American Urological Association Annual Meeting 99
Feb 03, 2012: Aeterna Zentaris Reports Updated Phase I Trial Results For AEZS-108 In Prostate Cancer At ASCO GCS Meeting 101

Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Table


Number of Products Under Development for Metastatic Hormone Refractory Prostate Cancer, H2 2012 10
Products under Development for Metastatic Hormone Refractory Prostate Cancer Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Bristol-Myers Squibb Company, H2 2012 21
AstraZeneca PLC, H2 2012 22
Genentech, Inc., H2 2012 23
Bavarian Nordic A/S, H2 2012 24
Millennium Pharmaceuticals, Inc., H2 2012 25
Astellas Pharma Inc., H2 2012 26
Teva Pharmaceutical Industries Limited, H2 2012 27
Active Biotech AB, H2 2012 28
Medivation, Inc., H2 2012 29
Cadila Pharmaceuticals Ltd., H2 2012 30
Ascenta Therapeutics, Inc., H2 2012 31
Bellicum Pharmaceuticals, Inc., H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 39
Metastatic Hormone Refractory Prostate Cancer Therapeutics Drug Profile Updates 82
Metastatic Hormone Refractory Prostate Cancer Therapeutics Discontinued Products 96
Metastatic Hormone Refractory Prostate Cancer Therapeutics Dormant Products 97
Metastatic Hormone Refractory Prostate Cancer Therapeutics Dormant Products (Contd..1) 98

List of Chart


Number of Products under Development for Metastatic Hormone Refractory Prostate Cancer, H2 2012 10
Products under Development for Metastatic Hormone Refractory Prostate Cancer Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Route of Administration, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Molecule Type, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *